Failure Prof. Nathan CLUMECK Head, Department of infectious diseases Saint-Pierre University Hospital Brussels, Belgium 6th EACS Advanced HIV Course Montpellier,
Boosted Protease Inhibitors. Current and Future Role in HIV Therapy.2014
Study sponsors LASA: Low dose Atazanavir/r vs. Standard dose Atazanavir/r The LASA study Atazanavir/ritonavir 200/100 mg is Non-inferior to 300/100 mg.
Percentage of patients with HIV-1 RNA PowerPoint PPT Presentation
